Gregory L Kearns
Overview
Explore the profile of Gregory L Kearns including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
102
Citations
2325
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Schluterman H, Linardos C, Drulia T, Marshall J, Kearns G
Front Pediatr
. 2024 Feb;
12:1350662.
PMID: 38390280
The palatability of pediatric pharmaceutical products plays a crucial role of influencing medication compliance. Rejection of unpalatable medications can potentially lead to treatment failure which can have immediate and delayed...
2.
Feldman K, Kearns G, Pearce R, Abdel-Rahman S, Leeder J, Friesen A, et al.
Clin Transl Sci
. 2022 Jan;
15(5):1155-1166.
PMID: 35099109
The C-pantoprazole breath test (PAN-BT) is a safe, noninvasive, in vivo CYP2C19 phenotyping probe for adults. Our objective was to evaluate PAN-BT performance in children, with a focus on discriminating...
3.
Thapa S, Luna R, Chumpitazi B, Oezguen N, Abdel-Rahman S, Garg U, et al.
Clin Transl Sci
. 2022 Jan;
15(4):1036-1049.
PMID: 35048535
Peppermint oil (PMO) is effective in the treatment of functional abdominal pain disorders, but its mechanism of action is unclear. Evidence suggests PMO has microbicidal activity. We investigated the effect...
4.
Shulman R, Chumpitazi B, Abdel-Rahman S, Garg U, Musaad S, Kearns G
Br J Clin Pharmacol
. 2021 Sep;
88(3):1321-1333.
PMID: 34528282
Aims: Little is known regarding the pharmacokinetics and pharmacodynamics of menthol, the active ingredient in peppermint oil (PMO). Our aim was to investigate the pharmacokinetics of menthol at 3 dose...
5.
Coker J, Ray-Griffith S, McLeod C, Han X, Mancino M, Kearns G, et al.
Arch Womens Ment Health
. 2021 Apr;
24(6):933-939.
PMID: 33864131
Buprenorphine is emerging as the preferred pharmacologic treatment for opioid use disorder during pregnancy. We examined the relative plasma clearance of buprenorphine (BUP) across pregnancy. Pregnant women with opioid use...
6.
Kearns G, van den Anker J
J Clin Pharmacol
. 2021 Apr;
61(6):740-743.
PMID: 33797778
No abstract available.
7.
Abdel-Rahman S, Bai S, Porter-Gill P, Goode G, Kearns G
Paediatr Drugs
. 2020 Nov;
23(1):95-104.
PMID: 33236188
Background: Medication refusal in children is largely driven by aversive taste profiles, which in turn influence adherence and therapeutic outcomes. However, there are no standardized methods for evaluating taste in...
8.
Goode G, Wagh S, Irby D, Ma D, Jacobs R, Kearns G, et al.
Pharm Dev Technol
. 2019 May;
24(8):1038-1043.
PMID: 31134840
Clindamycin's bitter taste and odor is known to affect treatment adherence in children. Recently, a formulation of clindamycin HCl complexed with ion exchange resin IRP 69 was shown to mask...
9.
Stancil S, Pearce R, Tyndale R, Kearns G, Vyhlidal C, Leeder J, et al.
Br J Clin Pharmacol
. 2019 Feb;
85(5):960-969.
PMID: 30706508
Aims: CYP2A6 is a genetically polymorphic enzyme resulting in differential substrate metabolism and health behaviours. Current phenotyping probes for CYP2A6 exhibit limitations related to procurement (deuterated cotinine), toxicity (coumarin), specificity...
10.
Shakhnovich V, Hornik C, Kearns G, Weigel J, Abdel-Rahman S
Clin Transl Sci
. 2019 Jan;
12(3):218-230.
PMID: 30657253
Despite a growing interest in, and commitment to, implementing pediatric clinical trials, approximately one in every five trials in children fails because of inappropriate study design, suboptimal experiment planning, or...